Match!
Shohei Mizuno
Aichi Medical University
36Publications
8H-index
206Citations
Publications 38
Newest
#1Masamitsu YanadaH-Index: 24
#2Akiyoshi Takami (Aichi Medical University)H-Index: 26
Last.Shingo Yano (Jikei University School of Medicine)H-Index: 13
view all 17 authors...
Autologous hematopoietic cell transplantation (HCT) has not gained universal popularity in the treatment of acute myeloid leukemia (AML), and its status remains unclear. To determine the implementation status and outcomes of autologous HCT for adults with AML in Japan, we analyzed data from 1,174 patients (including 446 with acute promyelocytic leukemia [APL]) who underwent autologous HCT between 1992 and 2016 consecutively reported to the Japanese nationwide transplantation registry. The annual...
1 CitationsSource
#1Hiroyuki Takamatsu (Kanazawa University)H-Index: 18
#2Shohei Mizuno (Aichi Medical University)H-Index: 8
Last.Kazutaka SunamiH-Index: 17
view all 14 authors...
Source
#1Shohei Mizuno (Aichi Medical University)H-Index: 8
#2Masamitsu YanadaH-Index: 24
Last.Akiyoshi Takami (Aichi Medical University)H-Index: 26
view all 17 authors...
Source
#1Shohei Mizuno (Aichi Medical University)H-Index: 8
#2Koji Kawamura (Jichi Medical University)H-Index: 9
Last.Akiyoshi Takami (Aichi Medical University)H-Index: 26
view all 18 authors...
Clinical trials evaluating the role of autologous hematopoietic stem cell transplantation (auto-HCT) in multiple myeloma have mostly included patients aged <65 years. Therefore, this study was aimed to evaluate the efficacy and safety of auto-HCT in elderly patients with multiple myeloma in the era of novel agents. We retrospectively analyzed 2056 patients with multiple myeloma, who underwent auto-HCT in 2007–2014 (287 were aged ≥65 years). We evaluated the 100-day treatment-related mortality (T...
1 CitationsSource
#1Takaaki Konuma (UTokyo: University of Tokyo)H-Index: 20
#2Tadakazu Kondo (Kyoto University)H-Index: 22
Last.Masamitsu YanadaH-Index: 24
view all 18 authors...
Abstract The optimal intensity of conditioning regimen may be dependent on not only age and comorbidities but also disease characteristics and risk of relapse after allogeneic hematopoietic cell transplantation (HCT). We, therefore, analyzed the transplant outcomes of 840 adult patients with cytogenetically poor-risk acute myeloid leukemia (AML) in first complete remission (CR1) who received first allogeneic HCT with either myeloablative conditioning (MAC; n=652) or reduced-intensity conditionin...
Source
#1Kaori UchinoH-Index: 2
#2Shohei MizunoH-Index: 8
Last.Akiyoshi TakamiH-Index: 26
view all 20 authors...
Source
#1Satoshi YamasakiH-Index: 44
#2Jun Aoki (Yokohama City University Medical Center)H-Index: 9
Last.Shingo Yano (Jikei University School of Medicine)H-Index: 13
view all 19 authors...
1 CitationsSource
#1Masamitsu Yanada (Fujita Health University)H-Index: 24
#2Masayoshi Masuko (Niigata University)H-Index: 13
Last.Shingo Yano (Jikei University School of Medicine)H-Index: 13
view all 21 authors...
It remains unclear how specific innovations in allogeneic hematopoietic cell transplantation (HCT) attained over the past decades have contributed to improvement in transplantation outcomes. To address this question, we conducted a registry-based study of adults with acute myeloid leukemia in first or second complete remission who underwent allogeneic HCT between 1994 and 2013 from a sibling (N = 1600) or unrelated (N = 2113) donor matched at the antigen level for HLA-A, -B, and -DR. Preliminary...
1 CitationsSource
#1Ayumu Takahashi (Aichi Medical University)H-Index: 8
#2Akihito Kubo (Aichi Medical University)H-Index: 20
Last.Etsuro Yamaguchi (Aichi Medical University)H-Index: 28
view all 13 authors...
1 CitationsSource
#1Takaaki Konuma (UTokyo: University of Tokyo)H-Index: 20
#2Kaito Harada (Tokai University)H-Index: 4
Last.Shingo Yano (Jikei University School of Medicine)H-Index: 13
view all 18 authors...
2 CitationsSource
1234